| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 145 | 2024 | 5598 | 8.180 |
Why?
|
| Gastrointestinal Microbiome | 40 | 2024 | 981 | 7.520 |
Why?
|
| Immunotherapy | 76 | 2024 | 3547 | 5.800 |
Why?
|
| Microbiota | 24 | 2024 | 546 | 5.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 53 | 2023 | 1329 | 4.020 |
Why?
|
| Neoplasms | 52 | 2024 | 15903 | 3.170 |
Why?
|
| Fecal Microbiota Transplantation | 12 | 2024 | 168 | 2.450 |
Why?
|
| Skin Neoplasms | 39 | 2024 | 4894 | 2.420 |
Why?
|
| Drug Resistance, Neoplasm | 42 | 2023 | 5407 | 2.260 |
Why?
|
| Programmed Cell Death 1 Receptor | 28 | 2022 | 1092 | 2.250 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 28 | 2021 | 1012 | 2.190 |
Why?
|
| Antigens, Neoplasm | 15 | 2024 | 1589 | 2.080 |
Why?
|
| Tumor Microenvironment | 37 | 2024 | 3022 | 1.940 |
Why?
|
| CTLA-4 Antigen | 22 | 2021 | 678 | 1.680 |
Why?
|
| Bacteria | 9 | 2023 | 654 | 1.570 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2024 | 1649 | 1.560 |
Why?
|
| B7-H1 Antigen | 17 | 2022 | 1071 | 1.540 |
Why?
|
| Molecular Targeted Therapy | 20 | 2022 | 2390 | 1.530 |
Why?
|
| T-Lymphocytes | 28 | 2023 | 3942 | 1.450 |
Why?
|
| Antineoplastic Agents, Immunological | 14 | 2023 | 1335 | 1.420 |
Why?
|
| Humans | 267 | 2024 | 271550 | 1.340 |
Why?
|
| Antibodies, Monoclonal | 16 | 2022 | 4493 | 1.310 |
Why?
|
| Pancreatic Neoplasms | 21 | 2023 | 5252 | 1.310 |
Why?
|
| Gastrointestinal Tract | 2 | 2023 | 326 | 1.230 |
Why?
|
| Dysbiosis | 5 | 2024 | 153 | 1.210 |
Why?
|
| Ipilimumab | 17 | 2023 | 759 | 1.210 |
Why?
|
| Probiotics | 5 | 2021 | 240 | 1.180 |
Why?
|
| Neoadjuvant Therapy | 25 | 2024 | 5224 | 1.090 |
Why?
|
| Protein Kinase Inhibitors | 35 | 2023 | 4961 | 1.090 |
Why?
|
| Immunomodulation | 5 | 2021 | 256 | 1.070 |
Why?
|
| Cancer Vaccines | 7 | 2024 | 754 | 0.990 |
Why?
|
| Indoles | 25 | 2017 | 1029 | 0.970 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2024 | 3396 | 0.920 |
Why?
|
| MAP Kinase Signaling System | 16 | 2017 | 886 | 0.910 |
Why?
|
| Oximes | 7 | 2018 | 191 | 0.890 |
Why?
|
| Dietary Fiber | 3 | 2024 | 129 | 0.860 |
Why?
|
| Animals | 84 | 2024 | 62359 | 0.840 |
Why?
|
| Melanoma, Experimental | 9 | 2021 | 382 | 0.830 |
Why?
|
| Antineoplastic Agents | 24 | 2023 | 14631 | 0.820 |
Why?
|
| Sulfonamides | 26 | 2017 | 1932 | 0.810 |
Why?
|
| Tumor Escape | 4 | 2022 | 247 | 0.810 |
Why?
|
| Mice | 67 | 2024 | 35697 | 0.750 |
Why?
|
| Pyrimidinones | 6 | 2018 | 318 | 0.750 |
Why?
|
| Cell Line, Tumor | 60 | 2024 | 14818 | 0.740 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 9 | 2023 | 383 | 0.730 |
Why?
|
| Monitoring, Immunologic | 3 | 2018 | 47 | 0.730 |
Why?
|
| Pyridones | 6 | 2018 | 361 | 0.720 |
Why?
|
| Immunity | 5 | 2021 | 356 | 0.720 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 157 | 0.700 |
Why?
|
| Tertiary Lymphoid Structures | 4 | 2021 | 36 | 0.700 |
Why?
|
| Carcinoma, Pancreatic Ductal | 11 | 2020 | 1824 | 0.680 |
Why?
|
| Th1 Cells | 1 | 2021 | 259 | 0.680 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2020 | 272 | 0.660 |
Why?
|
| Imidazoles | 8 | 2018 | 1058 | 0.650 |
Why?
|
| Biomarkers, Tumor | 27 | 2024 | 10736 | 0.640 |
Why?
|
| Neoplasm Proteins | 12 | 2020 | 3351 | 0.630 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2017 | 1018 | 0.590 |
Why?
|
| B-Lymphocytes | 8 | 2024 | 1427 | 0.580 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 625 | 0.570 |
Why?
|
| Prebiotics | 3 | 2023 | 35 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2024 | 16646 | 0.550 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 8 | 2018 | 42 | 0.540 |
Why?
|
| Adenocarcinoma | 10 | 2023 | 7937 | 0.520 |
Why?
|
| Carcinogenesis | 8 | 2024 | 1035 | 0.520 |
Why?
|
| Melanocytes | 10 | 2016 | 241 | 0.510 |
Why?
|
| Gene Targeting | 1 | 2016 | 316 | 0.500 |
Why?
|
| Mutation | 29 | 2023 | 15918 | 0.500 |
Why?
|
| Immunotherapy, Adoptive | 6 | 2022 | 1839 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2020 | 9053 | 0.490 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2020 | 1135 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2024 | 1052 | 0.460 |
Why?
|
| Colitis | 3 | 2022 | 343 | 0.460 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2016 | 381 | 0.450 |
Why?
|
| Pancreatectomy | 7 | 2013 | 696 | 0.450 |
Why?
|
| B7 Antigens | 3 | 2019 | 84 | 0.450 |
Why?
|
| Female | 90 | 2024 | 149106 | 0.450 |
Why?
|
| Middle Aged | 68 | 2024 | 90422 | 0.440 |
Why?
|
| Male | 78 | 2024 | 128724 | 0.430 |
Why?
|
| Biomarkers | 8 | 2023 | 5086 | 0.430 |
Why?
|
| Prognosis | 31 | 2022 | 22524 | 0.430 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 1065 | 0.430 |
Why?
|
| Lung Neoplasms | 11 | 2024 | 12032 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 9 | 2016 | 677 | 0.420 |
Why?
|
| Xenograft Model Antitumor Assays | 15 | 2019 | 3908 | 0.420 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2021 | 595 | 0.410 |
Why?
|
| Carcinoma, Merkel Cell | 3 | 2020 | 173 | 0.410 |
Why?
|
| Neoplasm Metastasis | 14 | 2021 | 5315 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 16 | 2024 | 7121 | 0.400 |
Why?
|
| Combined Modality Therapy | 11 | 2018 | 9049 | 0.390 |
Why?
|
| Treatment Outcome | 29 | 2024 | 33870 | 0.380 |
Why?
|
| Membrane Proteins | 7 | 2021 | 2949 | 0.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 5566 | 0.380 |
Why?
|
| Aged | 57 | 2024 | 73451 | 0.370 |
Why?
|
| Antigen Presentation | 3 | 2021 | 287 | 0.360 |
Why?
|
| Cytokines | 7 | 2019 | 2825 | 0.360 |
Why?
|
| Biomedical Research | 4 | 2020 | 801 | 0.360 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1951 | 0.360 |
Why?
|
| Adult | 53 | 2024 | 82003 | 0.330 |
Why?
|
| Lymph Nodes | 5 | 2021 | 3079 | 0.330 |
Why?
|
| Clostridium Infections | 2 | 2024 | 262 | 0.330 |
Why?
|
| Interleukin-6 | 3 | 2022 | 1054 | 0.330 |
Why?
|
| Inflammation | 5 | 2024 | 2531 | 0.330 |
Why?
|
| Interferon Type I | 2 | 2021 | 282 | 0.330 |
Why?
|
| Liposarcoma | 2 | 2024 | 248 | 0.330 |
Why?
|
| Immunity, Innate | 3 | 2019 | 690 | 0.320 |
Why?
|
| Antibodies | 4 | 2021 | 816 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2024 | 10370 | 0.320 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2015 | 187 | 0.310 |
Why?
|
| HLA-A Antigens | 3 | 2018 | 105 | 0.310 |
Why?
|
| Neoplasm Staging | 19 | 2022 | 14015 | 0.310 |
Why?
|
| Clone Cells | 4 | 2023 | 588 | 0.310 |
Why?
|
| Mast Cells | 2 | 2021 | 231 | 0.310 |
Why?
|
| Host-Pathogen Interactions | 3 | 2020 | 305 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2024 | 714 | 0.310 |
Why?
|
| Peptides | 3 | 2021 | 1505 | 0.300 |
Why?
|
| Sarcoma | 6 | 2024 | 1840 | 0.300 |
Why?
|
| Dendritic Cells | 5 | 2021 | 1109 | 0.290 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 1445 | 0.290 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 6 | 2016 | 471 | 0.290 |
Why?
|
| Bacteroides | 2 | 2024 | 54 | 0.280 |
Why?
|
| Anus Neoplasms | 2 | 2023 | 417 | 0.280 |
Why?
|
| GTP Phosphohydrolases | 3 | 2018 | 339 | 0.280 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 1916 | 0.280 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 357 | 0.270 |
Why?
|
| Monocytes | 2 | 2021 | 790 | 0.270 |
Why?
|
| Transcriptome | 5 | 2022 | 1953 | 0.270 |
Why?
|
| Feces | 4 | 2024 | 866 | 0.260 |
Why?
|
| Pancreas, Exocrine | 1 | 2005 | 23 | 0.260 |
Why?
|
| Genomics | 4 | 2023 | 2825 | 0.260 |
Why?
|
| Drug Eruptions | 2 | 2019 | 271 | 0.260 |
Why?
|
| Immune System | 3 | 2022 | 275 | 0.250 |
Why?
|
| Killer Cells, Natural | 4 | 2024 | 966 | 0.250 |
Why?
|
| Signal Transduction | 16 | 2021 | 12134 | 0.240 |
Why?
|
| Endometrial Neoplasms | 2 | 2024 | 1389 | 0.240 |
Why?
|
| Skin | 3 | 2018 | 1281 | 0.240 |
Why?
|
| Heterografts | 5 | 2017 | 742 | 0.240 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2024 | 38 | 0.240 |
Why?
|
| Lymphocytes | 2 | 2014 | 1279 | 0.240 |
Why?
|
| Precision Medicine | 5 | 2022 | 1206 | 0.240 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 7404 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 3 | 2023 | 1387 | 0.240 |
Why?
|
| Levonorgestrel | 1 | 2024 | 53 | 0.240 |
Why?
|
| Lymph Node Excision | 5 | 2022 | 2057 | 0.240 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2024 | 14 | 0.230 |
Why?
|
| Pancreas | 3 | 2020 | 745 | 0.230 |
Why?
|
| Macrophages | 6 | 2022 | 1360 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 1016 | 0.230 |
Why?
|
| RNA, Ribosomal, 16S | 6 | 2022 | 509 | 0.220 |
Why?
|
| Endometrial Hyperplasia | 1 | 2024 | 124 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 638 | 0.220 |
Why?
|
| MART-1 Antigen | 5 | 2016 | 113 | 0.220 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2020 | 243 | 0.220 |
Why?
|
| Mohs Surgery | 2 | 2018 | 102 | 0.220 |
Why?
|
| Aged, 80 and over | 26 | 2021 | 31066 | 0.220 |
Why?
|
| Immunohistochemistry | 8 | 2021 | 7790 | 0.210 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 560 | 0.210 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 10258 | 0.210 |
Why?
|
| Biopsy | 7 | 2023 | 3537 | 0.210 |
Why?
|
| Interferon-gamma | 6 | 2020 | 1182 | 0.210 |
Why?
|
| Fucose | 1 | 2023 | 58 | 0.210 |
Why?
|
| Cohort Studies | 9 | 2021 | 9477 | 0.210 |
Why?
|
| Oxidative Phosphorylation | 4 | 2020 | 272 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2019 | 2359 | 0.200 |
Why?
|
| Graft vs Host Disease | 2 | 2024 | 2809 | 0.200 |
Why?
|
| Coenzyme A | 1 | 2021 | 10 | 0.200 |
Why?
|
| Body Mass Index | 3 | 2023 | 2247 | 0.200 |
Why?
|
| Intestinal Mucosa | 4 | 2023 | 1122 | 0.200 |
Why?
|
| Gene Expression Profiling | 7 | 2023 | 5163 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2019 | 1474 | 0.200 |
Why?
|
| DNA Mutational Analysis | 4 | 2016 | 2357 | 0.200 |
Why?
|
| Prospective Studies | 11 | 2024 | 13385 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2020 | 3988 | 0.200 |
Why?
|
| Stromal Cells | 4 | 2020 | 832 | 0.200 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 51 | 0.200 |
Why?
|
| Diet | 4 | 2024 | 1483 | 0.200 |
Why?
|
| Ultraviolet Rays | 3 | 2012 | 587 | 0.200 |
Why?
|
| Multiprotein Complexes | 2 | 2014 | 389 | 0.200 |
Why?
|
| PAX3 Transcription Factor | 2 | 2018 | 36 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 102 | 0.190 |
Why?
|
| Oncogenes | 3 | 2020 | 700 | 0.190 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2021 | 19 | 0.190 |
Why?
|
| Immunologic Factors | 2 | 2022 | 669 | 0.190 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2024 | 299 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 149 | 0.190 |
Why?
|
| Drug Synergism | 3 | 2020 | 1360 | 0.190 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 249 | 0.190 |
Why?
|
| Bevacizumab | 1 | 2024 | 957 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2020 | 499 | 0.180 |
Why?
|
| Nanomedicine | 1 | 2020 | 53 | 0.180 |
Why?
|
| Diet Therapy | 1 | 2021 | 52 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 1466 | 0.180 |
Why?
|
| Membrane Glycoproteins | 2 | 2019 | 1104 | 0.180 |
Why?
|
| Phenotype | 11 | 2021 | 6493 | 0.180 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2010 | 227 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2021 | 299 | 0.180 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 1554 | 0.180 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 131 | 0.180 |
Why?
|
| Receptors, Androgen | 2 | 2024 | 858 | 0.180 |
Why?
|
| Tongue Neoplasms | 1 | 2022 | 253 | 0.180 |
Why?
|
| Oncogenic Viruses | 1 | 2020 | 24 | 0.180 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 22 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2020 | 6845 | 0.170 |
Why?
|
| Frameshift Mutation | 1 | 2020 | 235 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2018 | 683 | 0.170 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.170 |
Why?
|
| Symbiosis | 1 | 2020 | 76 | 0.170 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2020 | 113 | 0.170 |
Why?
|
| Deoxycytidine | 2 | 2017 | 1390 | 0.170 |
Why?
|
| Interleukin-1beta | 3 | 2021 | 297 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 481 | 0.170 |
Why?
|
| Survival Rate | 12 | 2022 | 12528 | 0.170 |
Why?
|
| Wnt Signaling Pathway | 3 | 2017 | 444 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 148 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2017 | 1545 | 0.160 |
Why?
|
| Aging | 2 | 2018 | 1555 | 0.160 |
Why?
|
| Phosphoproteins | 2 | 2015 | 1219 | 0.160 |
Why?
|
| POU Domain Factors | 1 | 2018 | 13 | 0.160 |
Why?
|
| Lichenoid Eruptions | 1 | 2019 | 37 | 0.160 |
Why?
|
| Survival Analysis | 7 | 2022 | 9307 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2017 | 161 | 0.160 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 583 | 0.160 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2019 | 150 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 3675 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 3 | 2016 | 654 | 0.160 |
Why?
|
| Lymphatic Metastasis | 9 | 2021 | 4965 | 0.160 |
Why?
|
| Antigens, Bacterial | 1 | 2021 | 374 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2014 | 1568 | 0.160 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2016 | 155 | 0.160 |
Why?
|
| Biological Variation, Individual | 1 | 2018 | 3 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 299 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 4061 | 0.160 |
Why?
|
| High-Throughput Screening Assays | 2 | 2017 | 206 | 0.160 |
Why?
|
| Pancreaticoduodenectomy | 5 | 2013 | 706 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 384 | 0.160 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 3850 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Xanthomatosis | 1 | 2018 | 22 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2022 | 889 | 0.150 |
Why?
|
| Sentinel Lymph Node | 1 | 2021 | 229 | 0.150 |
Why?
|
| Escherichia coli | 1 | 2024 | 1309 | 0.150 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2018 | 47 | 0.150 |
Why?
|
| Neutropenia | 1 | 2022 | 1001 | 0.150 |
Why?
|
| Azacitidine | 3 | 2014 | 1219 | 0.150 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 151 | 0.150 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 2348 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 1403 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2023 | 5606 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2023 | 531 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 290 | 0.150 |
Why?
|
| Fibronectins | 2 | 2015 | 208 | 0.150 |
Why?
|
| Histiocytes | 1 | 2018 | 95 | 0.150 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 211 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 6 | 2023 | 5762 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2024 | 1347 | 0.150 |
Why?
|
| HLA Antigens | 1 | 2021 | 594 | 0.150 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 2028 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 5771 | 0.150 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 331 | 0.150 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2017 | 26 | 0.150 |
Why?
|
| Protein Biosynthesis | 2 | 2020 | 1032 | 0.150 |
Why?
|
| Obesity | 5 | 2024 | 2915 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 135 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2020 | 441 | 0.150 |
Why?
|
| Pathology | 1 | 2018 | 108 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2020 | 453 | 0.140 |
Why?
|
| Mice, Nude | 8 | 2019 | 4348 | 0.140 |
Why?
|
| ErbB Receptors | 3 | 2020 | 2380 | 0.140 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 485 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 309 | 0.140 |
Why?
|
| Environment | 1 | 2018 | 174 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 764 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2021 | 4955 | 0.140 |
Why?
|
| Gene Expression | 4 | 2019 | 3658 | 0.140 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 670 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2022 | 734 | 0.140 |
Why?
|
| Genome | 2 | 2017 | 690 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1053 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2018 | 116 | 0.140 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 42 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 619 | 0.140 |
Why?
|
| Granuloma | 1 | 2018 | 159 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 3184 | 0.140 |
Why?
|
| Gastritis | 1 | 2020 | 405 | 0.140 |
Why?
|
| Intestines | 1 | 2021 | 739 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 4139 | 0.130 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 274 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2018 | 751 | 0.130 |
Why?
|
| Guanidines | 1 | 2016 | 61 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 482 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 7011 | 0.130 |
Why?
|
| Mucor | 1 | 2015 | 18 | 0.130 |
Why?
|
| Lactams, Macrocyclic | 1 | 2016 | 90 | 0.130 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 221 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 4 | 2024 | 2462 | 0.130 |
Why?
|
| Standard of Care | 1 | 2018 | 275 | 0.130 |
Why?
|
| Transcription Factors | 6 | 2016 | 5451 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2018 | 210 | 0.130 |
Why?
|
| Drug Tolerance | 1 | 2016 | 123 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 530 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2019 | 606 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 659 | 0.130 |
Why?
|
| Genome, Fungal | 1 | 2015 | 56 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 2616 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2016 | 165 | 0.130 |
Why?
|
| Down-Regulation | 5 | 2023 | 2096 | 0.130 |
Why?
|
| Cell Proliferation | 10 | 2020 | 7259 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 543 | 0.130 |
Why?
|
| Cell Division | 1 | 2020 | 2685 | 0.130 |
Why?
|
| Collagen | 1 | 2018 | 729 | 0.130 |
Why?
|
| Lymphocyte Activation | 5 | 2021 | 1722 | 0.130 |
Why?
|
| Mitochondrial Dynamics | 1 | 2016 | 67 | 0.130 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2015 | 110 | 0.130 |
Why?
|
| Pneumonia | 2 | 2019 | 798 | 0.130 |
Why?
|
| raf Kinases | 2 | 2013 | 80 | 0.130 |
Why?
|
| Mice, SCID | 5 | 2018 | 1831 | 0.130 |
Why?
|
| Mice, Knockout | 7 | 2024 | 5750 | 0.120 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 1240 | 0.120 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 21 | 0.120 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2014 | 30 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 549 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 1586 | 0.120 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 125 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 631 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 682 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 329 | 0.120 |
Why?
|
| Retrospective Studies | 16 | 2023 | 39818 | 0.120 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 56 | 0.120 |
Why?
|
| Mice, Inbred NOD | 4 | 2018 | 900 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 689 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2015 | 118 | 0.120 |
Why?
|
| Immunocompetence | 1 | 2014 | 73 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 214 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 237 | 0.110 |
Why?
|
| Monophenol Monooxygenase | 2 | 2012 | 60 | 0.110 |
Why?
|
| Mutagenesis | 2 | 2012 | 520 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 790 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 262 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 139 | 0.110 |
Why?
|
| Uveal Neoplasms | 1 | 2016 | 194 | 0.110 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2019 | 530 | 0.110 |
Why?
|
| Phosphorylation | 6 | 2018 | 4976 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1071 | 0.110 |
Why?
|
| Computational Biology | 1 | 2020 | 1280 | 0.110 |
Why?
|
| Coculture Techniques | 4 | 2021 | 631 | 0.110 |
Why?
|
| Homeostasis | 1 | 2018 | 933 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 362 | 0.110 |
Why?
|
| Young Adult | 12 | 2021 | 22190 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 2419 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 128 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2020 | 7262 | 0.110 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2013 | 57 | 0.110 |
Why?
|
| Hypoxia | 1 | 2016 | 473 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2016 | 1018 | 0.110 |
Why?
|
| Apoptosis | 8 | 2014 | 7783 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 1125 | 0.110 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2012 | 8 | 0.110 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2010 | 85 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2022 | 1453 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1317 | 0.110 |
Why?
|
| Hair Color | 1 | 2012 | 22 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2019 | 1035 | 0.110 |
Why?
|
| Skin Pigmentation | 1 | 2012 | 50 | 0.110 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 85 | 0.110 |
Why?
|
| Pancreatic Fistula | 1 | 2013 | 102 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 916 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2422 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 353 | 0.100 |
Why?
|
| Mucus | 2 | 2022 | 109 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 379 | 0.100 |
Why?
|
| Incidental Findings | 2 | 2011 | 282 | 0.100 |
Why?
|
| Leucovorin | 1 | 2013 | 345 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2015 | 1713 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 3 | 2022 | 680 | 0.100 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 54 | 0.100 |
Why?
|
| Cell Survival | 5 | 2017 | 3068 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 202 | 0.100 |
Why?
|
| Sunlight | 1 | 2012 | 80 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 4 | 2016 | 1081 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 1022 | 0.100 |
Why?
|
| Tumor Burden | 5 | 2016 | 2034 | 0.100 |
Why?
|
| Adoptive Transfer | 3 | 2016 | 431 | 0.100 |
Why?
|
| Cells, Cultured | 6 | 2018 | 5740 | 0.100 |
Why?
|
| Mice, Mutant Strains | 2 | 2020 | 654 | 0.100 |
Why?
|
| Mitochondria | 2 | 2016 | 1301 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2012 | 443 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1968 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 440 | 0.100 |
Why?
|
| Mucins | 2 | 2022 | 289 | 0.100 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 331 | 0.090 |
Why?
|
| Australia | 2 | 2023 | 263 | 0.090 |
Why?
|
| Time Factors | 7 | 2021 | 13077 | 0.090 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 164 | 0.090 |
Why?
|
| Peripheral Nerves | 1 | 2011 | 161 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1380 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1350 | 0.090 |
Why?
|
| Spleen | 2 | 2011 | 724 | 0.090 |
Why?
|
| Proteomics | 4 | 2023 | 1431 | 0.090 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 660 | 0.090 |
Why?
|
| Plasma Cells | 2 | 2022 | 200 | 0.090 |
Why?
|
| Valproic Acid | 1 | 2012 | 274 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 2475 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2011 | 232 | 0.090 |
Why?
|
| Diphenylamine | 1 | 2010 | 16 | 0.090 |
Why?
|
| Duodenal Neoplasms | 1 | 2011 | 139 | 0.090 |
Why?
|
| Single-Cell Analysis | 3 | 2020 | 552 | 0.090 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 6205 | 0.090 |
Why?
|
| Butadienes | 1 | 2010 | 36 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2021 | 1774 | 0.090 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2011 | 93 | 0.090 |
Why?
|
| Camptothecin | 1 | 2013 | 539 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 2011 | 113 | 0.090 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2010 | 94 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 704 | 0.090 |
Why?
|
| CD8 Antigens | 2 | 2016 | 173 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 185 | 0.090 |
Why?
|
| DNA Methylation | 3 | 2022 | 2761 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 2572 | 0.090 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2020 | 40 | 0.090 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 1351 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 876 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 4800 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 87 | 0.090 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2012 | 294 | 0.090 |
Why?
|
| T Cell Transcription Factor 1 | 2 | 2020 | 9 | 0.090 |
Why?
|
| Quality of Life | 4 | 2024 | 4764 | 0.080 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 455 | 0.080 |
Why?
|
| Oxidoreductases | 1 | 2010 | 168 | 0.080 |
Why?
|
| Pancreatic Cyst | 1 | 2010 | 114 | 0.080 |
Why?
|
| Disease Progression | 4 | 2023 | 6857 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2022 | 2902 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1590 | 0.080 |
Why?
|
| Risk Factors | 7 | 2023 | 17982 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2013 | 741 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2013 | 581 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6264 | 0.080 |
Why?
|
| Benzamides | 2 | 2014 | 1879 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2013 | 1989 | 0.080 |
Why?
|
| Histones | 1 | 2016 | 1513 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 580 | 0.080 |
Why?
|
| Alternative Splicing | 1 | 2011 | 612 | 0.080 |
Why?
|
| Complementarity Determining Regions | 1 | 2008 | 44 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 4651 | 0.080 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2009 | 182 | 0.080 |
Why?
|
| Testis | 1 | 2012 | 745 | 0.080 |
Why?
|
| Mice, Transgenic | 4 | 2021 | 4249 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2016 | 2078 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2020 | 380 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 1950 | 0.070 |
Why?
|
| Codon | 2 | 2020 | 261 | 0.070 |
Why?
|
| Protein Binding | 3 | 2023 | 3497 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2019 | 190 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 560 | 0.070 |
Why?
|
| Cysteine | 1 | 2008 | 213 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 2323 | 0.070 |
Why?
|
| Algorithms | 3 | 2024 | 3925 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2023 | 6234 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 15247 | 0.070 |
Why?
|
| HLA-A2 Antigen | 3 | 2016 | 172 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2008 | 7792 | 0.070 |
Why?
|
| Italy | 2 | 2017 | 190 | 0.070 |
Why?
|
| Antigens, CD | 3 | 2021 | 1429 | 0.070 |
Why?
|
| Exome | 3 | 2020 | 1249 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2016 | 427 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2018 | 1659 | 0.070 |
Why?
|
| Texas | 1 | 2018 | 6444 | 0.070 |
Why?
|
| Ki-67 Antigen | 2 | 2021 | 682 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2010 | 1859 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2659 | 0.070 |
Why?
|
| Benzimidazoles | 3 | 2014 | 438 | 0.070 |
Why?
|
| Cystadenocarcinoma | 1 | 2005 | 25 | 0.070 |
Why?
|
| Thyroid Neoplasms | 2 | 2014 | 1884 | 0.070 |
Why?
|
| RNA, Messenger | 4 | 2022 | 6436 | 0.070 |
Why?
|
| Cystadenoma | 1 | 2005 | 29 | 0.070 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 1436 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 5082 | 0.070 |
Why?
|
| Metagenome | 2 | 2017 | 193 | 0.060 |
Why?
|
| Decision Trees | 1 | 2005 | 181 | 0.060 |
Why?
|
| Ribosomal Protein S6 | 2 | 2016 | 46 | 0.060 |
Why?
|
| Nitriles | 1 | 2010 | 938 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 5030 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 2008 | 224 | 0.060 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2005 | 87 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2016 | 1316 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 723 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 17 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 2274 | 0.060 |
Why?
|
| Isoantigens | 1 | 2004 | 66 | 0.060 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 77 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 2203 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2016 | 2438 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2017 | 3073 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 2017 | 1728 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2022 | 2357 | 0.060 |
Why?
|
| Lewis X Antigen | 1 | 2024 | 41 | 0.060 |
Why?
|
| Lectins, C-Type | 2 | 2021 | 163 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2008 | 526 | 0.060 |
Why?
|
| Adolescent | 7 | 2021 | 32726 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 1166 | 0.060 |
Why?
|
| Fucosyltransferases | 1 | 2024 | 78 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 1823 | 0.060 |
Why?
|
| Genotype | 3 | 2020 | 4266 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1886 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2023 | 59 | 0.060 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2023 | 23 | 0.060 |
Why?
|
| Glycosylation | 1 | 2024 | 230 | 0.060 |
Why?
|
| HT29 Cells | 2 | 2015 | 157 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 5870 | 0.050 |
Why?
|
| Germ-Free Life | 1 | 2023 | 67 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2018 | 703 | 0.050 |
Why?
|
| Xylose | 1 | 2022 | 18 | 0.050 |
Why?
|
| Doxycycline | 2 | 2015 | 179 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 3708 | 0.050 |
Why?
|
| HLA-DRB1 Chains | 1 | 2023 | 89 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 79 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2023 | 111 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 2857 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2014 | 276 | 0.050 |
Why?
|
| Fusobacterium | 1 | 2022 | 12 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 1138 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2023 | 133 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 63 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2010 | 1713 | 0.050 |
Why?
|
| Vancomycin | 1 | 2024 | 292 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 64 | 0.050 |
Why?
|
| Dinucleoside Phosphates | 1 | 2021 | 25 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2023 | 196 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 310 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 59 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2012 | 337 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 118 | 0.050 |
Why?
|
| Phagocytes | 1 | 2021 | 43 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 5099 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2021 | 3347 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 430 | 0.050 |
Why?
|
| Quinazolines | 2 | 2017 | 956 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 195 | 0.050 |
Why?
|
| Frameshifting, Ribosomal | 1 | 2020 | 4 | 0.050 |
Why?
|
| Virus Physiological Phenomena | 1 | 2021 | 18 | 0.050 |
Why?
|
| Anal Canal | 1 | 2022 | 238 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2021 | 170 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2021 | 103 | 0.050 |
Why?
|
| Androgens | 1 | 2024 | 513 | 0.050 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2020 | 19 | 0.050 |
Why?
|
| Genes, ras | 2 | 2015 | 680 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 273 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 1527 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 1697 | 0.050 |
Why?
|
| Tryptophan | 1 | 2020 | 143 | 0.040 |
Why?
|
| Metabolomics | 1 | 2024 | 505 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 67 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 462 | 0.040 |
Why?
|
| Awareness | 1 | 2021 | 114 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2021 | 4157 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 257 | 0.040 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 20 | 0.040 |
Why?
|
| Receptors, CXCR5 | 1 | 2020 | 29 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 280 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2015 | 1463 | 0.040 |
Why?
|
| Ribosomes | 1 | 2020 | 168 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 5185 | 0.040 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2019 | 36 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 36 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 4153 | 0.040 |
Why?
|
| DNA Fingerprinting | 1 | 2019 | 181 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2021 | 295 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2020 | 207 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 486 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 328 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2019 | 90 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2021 | 427 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 323 | 0.040 |
Why?
|
| Homozygote | 1 | 2021 | 767 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2017 | 1564 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 2588 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 4337 | 0.040 |
Why?
|
| Lung | 2 | 2020 | 3300 | 0.040 |
Why?
|
| Faecalibacterium | 1 | 2018 | 5 | 0.040 |
Why?
|
| Back | 1 | 2018 | 49 | 0.040 |
Why?
|
| Apyrase | 1 | 2018 | 40 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 116 | 0.040 |
Why?
|
| Bacteroides fragilis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4976 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2019 | 264 | 0.040 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 234 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 433 | 0.040 |
Why?
|
| Base Sequence | 2 | 2018 | 5453 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 232 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 868 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 5848 | 0.040 |
Why?
|
| Sirolimus | 1 | 2022 | 837 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2018 | 192 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2012 | 1820 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 316 | 0.040 |
Why?
|
| Mycoplasma hyorhinis | 1 | 2017 | 5 | 0.040 |
Why?
|
| Bifidobacterium | 1 | 2018 | 63 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 229 | 0.040 |
Why?
|
| Gammaproteobacteria | 1 | 2017 | 20 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2018 | 279 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2018 | 106 | 0.040 |
Why?
|
| Dermatology | 1 | 2018 | 72 | 0.040 |
Why?
|
| United States | 3 | 2020 | 16006 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 70 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2020 | 696 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 552 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 293 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 67 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 97 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 442 | 0.040 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2017 | 58 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 135 | 0.040 |
Why?
|
| Systems Biology | 1 | 2017 | 114 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2018 | 302 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2017 | 241 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 3244 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1065 | 0.030 |
Why?
|
| Pyridines | 2 | 2014 | 1310 | 0.030 |
Why?
|
| Proteome | 1 | 2020 | 573 | 0.030 |
Why?
|
| Software | 1 | 2024 | 1392 | 0.030 |
Why?
|
| Models, Biological | 2 | 2018 | 3207 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2018 | 339 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 3156 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 206 | 0.030 |
Why?
|
| Merkel cell polyomavirus | 1 | 2016 | 31 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2017 | 471 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2018 | 314 | 0.030 |
Why?
|
| Nelfinavir | 1 | 2016 | 16 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2016 | 32 | 0.030 |
Why?
|
| Hematoxylin | 1 | 2016 | 34 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2016 | 72 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 454 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 690 | 0.030 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 1442 | 0.030 |
Why?
|
| Ovary | 1 | 2020 | 699 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 69 | 0.030 |
Why?
|
| DNA Damage | 2 | 2016 | 1987 | 0.030 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2016 | 65 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 355 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Wnt1 Protein | 1 | 2016 | 101 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 248 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 220 | 0.030 |
Why?
|
| Onychomycosis | 1 | 2015 | 18 | 0.030 |
Why?
|
| Observer Variation | 2 | 2008 | 719 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 3220 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2015 | 33 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 74 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 94 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 421 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1209 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2017 | 475 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 823 | 0.030 |
Why?
|
| Proteins | 1 | 2004 | 2050 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2016 | 133 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 257 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 276 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 327 | 0.030 |
Why?
|
| Integrin alpha5beta1 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2016 | 234 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 2199 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 121 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7916 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 320 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 4582 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 3621 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 759 | 0.030 |
Why?
|
| Fungemia | 1 | 2015 | 119 | 0.030 |
Why?
|
| Length of Stay | 2 | 2013 | 2010 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 296 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2016 | 189 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 531 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 107 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 69 | 0.030 |
Why?
|
| Benzocycloheptenes | 1 | 2014 | 11 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2015 | 271 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 1019 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 459 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 166 | 0.030 |
Why?
|
| Granzymes | 1 | 2014 | 95 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4807 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1556 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 400 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 6706 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 296 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 787 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 824 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 223 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1715 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 357 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 592 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 200 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2013 | 32 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 288 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 377 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 629 | 0.030 |
Why?
|
| Ileus | 1 | 2013 | 30 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 901 | 0.030 |
Why?
|
| Boston | 1 | 2013 | 135 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 1115 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1378 | 0.030 |
Why?
|
| Research | 1 | 2016 | 431 | 0.030 |
Why?
|
| Groin | 1 | 2013 | 78 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2013 | 98 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 701 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2013 | 99 | 0.030 |
Why?
|
| Massachusetts | 1 | 2013 | 148 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2594 | 0.030 |
Why?
|
| Failure to Thrive | 1 | 2013 | 96 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 688 | 0.030 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2012 | 10 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 62 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 4505 | 0.030 |
Why?
|
| Peroxidases | 1 | 2012 | 30 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 5373 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 2314 | 0.030 |
Why?
|
| Melanins | 1 | 2012 | 47 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 577 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 189 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2013 | 116 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 130 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2012 | 123 | 0.030 |
Why?
|
| Methylation | 1 | 2014 | 625 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2013 | 401 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2014 | 206 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1250 | 0.030 |
Why?
|
| Cystadenoma, Serous | 1 | 2012 | 31 | 0.030 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2012 | 35 | 0.030 |
Why?
|
| Operative Time | 1 | 2013 | 249 | 0.030 |
Why?
|
| Neurofibromin 1 | 1 | 2012 | 84 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 425 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2012 | 103 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 691 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2012 | 181 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2014 | 711 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2017 | 1006 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2012 | 110 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 717 | 0.020 |
Why?
|
| Anilides | 1 | 2014 | 294 | 0.020 |
Why?
|
| Patient Selection | 1 | 2019 | 2033 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 662 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 827 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2364 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 1008 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2015 | 875 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 71 | 0.020 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2013 | 273 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 400 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2010 | 85 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 657 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 878 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 1389 | 0.020 |
Why?
|
| Cisplatin | 1 | 2017 | 2501 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2010 | 275 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2017 | 2104 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 590 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 583 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 1121 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2013 | 767 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 3130 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 481 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2014 | 1690 | 0.020 |
Why?
|
| Triazoles | 1 | 2014 | 629 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 1147 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2018 | 1462 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2015 | 876 | 0.020 |
Why?
|
| Gene Library | 1 | 2010 | 353 | 0.020 |
Why?
|
| Retroviridae | 1 | 2010 | 373 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 854 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 465 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2199 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1206 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 276 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 2033 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 495 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 562 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1193 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 1993 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 564 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1087 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 614 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2008 | 41 | 0.020 |
Why?
|
| Iohexol | 1 | 2008 | 56 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2010 | 379 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3496 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1384 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 842 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1341 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1744 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2016 | 1699 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 2484 | 0.020 |
Why?
|
| Critical Care | 1 | 2013 | 803 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 3610 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1581 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2012 | 5697 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 1137 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 2435 | 0.020 |
Why?
|
| Piperazines | 1 | 2014 | 2145 | 0.020 |
Why?
|
| Minor Histocompatibility Loci | 1 | 2004 | 5 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2004 | 11 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 2004 | 51 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2011 | 1012 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2004 | 92 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2459 | 0.010 |
Why?
|
| Radiosurgery | 1 | 2013 | 1378 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 248 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 191 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 912 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 283 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 311 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2004 | 316 | 0.010 |
Why?
|
| Smoking | 1 | 2012 | 2549 | 0.010 |
Why?
|
| Child | 2 | 2016 | 30545 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 487 | 0.010 |
Why?
|
| Epitopes | 1 | 2004 | 707 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2004 | 211 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2014 | 3662 | 0.010 |
Why?
|
| Contrast Media | 1 | 2008 | 1504 | 0.010 |
Why?
|
| Brain | 1 | 2013 | 4229 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 1731 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 4895 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 16221 | 0.000 |
Why?
|